BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Business

  Cara Therapeutics, Inc. Names Eric J. Vandal Vice President, Commercial Operations

  June 2, 2014

   · 

  1 min read
• Drug Development

  Janssen-Cilag International NV Release: Phase 3 Data Highlight Benefits Of Using VELCADE® Within Frontline Treatment Of Mantle Cell Lymphoma, With Results Showing Significantly Longer Progression-Free Survival Compared To Standard Of Care

  June 2, 2014

   · 

  1 min read
• Drug Development

  Ignyta Announces Interim Data From RXDX-101 Phase I Clinical Trial

  June 2, 2014

   · 

  1 min read
• Deals

  Endo Completes Sale Of Early Stage Drug Discovery Portfolio

  June 2, 2014

   · 

  3 min read
• Policy

  IGI Laboratories, Inc. Announces Fifteenth ANDA Submission

  June 2, 2014

   · 

  2 min read
• Drug Development

  Karyopharm Therapeutics Provides Data Update For Selinexor In Non-Hodgkin’s Lymphoma And Acute Myeloid Leukemia At 2014 American Society of Clinical Oncology Annual Meeting

  June 2, 2014

   · 

  1 min read
• Drug Development

  Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity And Progression-Free Survival (PFS) In Updated Phase 1/2 Study Results In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  June 2, 2014

   · 

  1 min read
• Drug Development

  Ariad Pharmaceuticals, Inc. Announces Preliminary Safety And Efficacy Data Of Ponatinib In Patients With Newly Diagnosed CML From Discontinued Phase 3 EPIC Trial

  June 2, 2014

   · 

  1 min read
• Drug Development

  Cyclacel Pharmaceuticals, Inc. Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS)

  June 2, 2014

   · 

  1 min read
• Drug Development

  Verastem, Inc. Presents Updated Clinical Data From VS-6063 And Paclitaxel Combination Phase 1/1b Study In Patients With Ovarian Cancer At The 2014 American Society of Clinical Oncology Annual Meeting

  June 2, 2014

   · 

  1 min read